AstraZeneca Plc. sold some rights to its asthma drug Symbicort [budesonide and formoterol fumarate dihydrate] in Japan to Astellas Pharma Inc. for a one-time payment of three billion yen with up to 5.5 billion yen if certain sales quotas are met.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지